• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director New Jason Griffin covered exercise/tax liability with 257,794 shares, gifted 218,456 shares, received a gift of 218,456 shares and was granted 952,500 shares (SEC Form 4)

    11/14/25 5:11:08 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETHZ alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    New Jason Griffin

    (Last) (First) (Middle)
    2875 SOUTH OCEAN BLVD,
    SUITE 200

    (Street)
    PALM BEACH FL 33480

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ETHZilla Corp [ ETHZ ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/12/2025 A 952,500(1) A $0.00(2) 952,500 D
    Common Stock 11/12/2025 F 257,794(3) D $0.00 711,424 D
    Common Stock 11/14/2025 G(4) 218,456 D $0.00 492,250 D
    Common Stock 11/14/2025 G(4) 218,456 A $0.00 218,456 I By New Island Advisors LLC(5)
    Common Stock 56,603 I By New Island Capital LLC(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. 476,250 shares vested on the grant date and 476,250 shares vest on January 2, 2026.
    2. Issued in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.
    3. A total of 257,794 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 476,250 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).
    4. On November 14, 2025, the Reporting Person transferred 218,456 shares of common stock to New Island Advisors LLC, which is managed by the Reporting Person for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.
    5. The Reporting Person is the founder and managing partner of New Island Advisors LLC, and therefore deemed to beneficially own the securities held by such entity. Mr. New disclaims beneficial ownership of the securities owned directly by New Island Advisors LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
    6. The Reporting Person is the founder and managing partner of New Island Capital LLC, and therefore deemed to beneficially own the securities held by such entity. Mr. New disclaims beneficial ownership of the securities owned directly by New Island Capital LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
    /s/ Jason New 11/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ETHZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETHZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ETHZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rudisill Mcandrew was granted 1,365,000 shares, covered exercise/tax liability with 271,635 shares, gifted 410,865 shares and received a gift of 370,000 shares (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    11/17/25 8:00:02 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heter Crystal Jane received a gift of 182,742 shares, was granted 649,748 shares, covered exercise/tax liability with 142,132 shares and gifted 182,742 shares (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    11/14/25 5:18:39 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suckling Andrew P was granted 649,748 shares, covered exercise/tax liability with 175,854 shares, gifted 149,020 shares and received a gift of 149,020 shares (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    11/14/25 5:17:03 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    SEC Filings

    View All

    SEC Form 10-Q filed by ETHZilla Corporation

    10-Q - ETHZilla Corp (0001690080) (Filer)

    11/14/25 5:04:21 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ETHZilla Corporation

    SCHEDULE 13G/A - ETHZilla Corp (0001690080) (Subject)

    11/14/25 4:24:49 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    11/14/25 8:01:51 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Reports Third Quarter 2025 Financial Results

    Company generates $4.1 million in revenue in first six weeks operating as ETHZilla; Accelerates RWA tokenization initiatives PALM BEACH, Fla., Nov. 14, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance (DeFi), today announced financial results for the third quarter ended September 30, 2025. Management Commentary "This quarter marked a transformative leap for ETHZilla, establishing us as a technology leader in DeFi and positioning us for real-world asset (RWA) toke

    11/14/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Promotes John T. Saunders to Chief Financial Officer

    PALM BEACH, Fla., Nov. 14, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance (DeFi), today announced the promotion of John T. Saunders to senior vice president, chief financial officer (CFO). Saunders will continue to report to McAndrew Rudisill, chairman and CEO, and to the audit committee. In his expanded role, Saunders will oversee financial strategy, reporting and analysis, internal controls, information technology and operations. He previously served as vice president, finance. "

    11/14/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Sells Approximately $40mm ETH to Facilitate Stock Repurchases

    Company has repurchased approximately 600k shares for about $12 million since Oct. 24, 2025 Company is buying back shares at a significant discount to NAV PALM BEACH, Fla., Oct. 27, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ)("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance, today announced that it sold approximately $40 million of its ETH treasury holdings and plans to use the proceeds for share repurchases. Since executing the sale on Oct. 24, 2025, the Company has repurchased approximately 600,000 shares of its common stock for approximately $12 million under its existing board authorized $250 million stock repurchase

    10/27/25 4:00:00 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Leadership Updates

    Live Leadership Updates

    View All

    ETHZilla names John Kristoff as SVP, Corporate Communications and Investor Relations

    PALM BEACH, Fla., Oct. 16, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance, today announced the appointment of John D. Kristoff as Senior Vice President, Corporate Communications and Investor Relations. He will report directly to Chairman and CEO McAndrew Rudisill. In this newly created role, Kristoff will lead ETHZilla's communications and investor relations strategies, shaping the company's narrative and deepening engagement with both the media and investors. He will also play a k

    10/16/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Appointment of Jason New to Board of Directors

    PALM BEACH, Fla., Oct. 8, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), today announced that Jason New, Vice Chairman of Investment Banking at Lazard, has been appointed as a member of its Board of Directors, effective immediately. Mr. New brings more than two decades of experience in global credit, private equity, and alternative investments. He previously co-founded NovaWulf Management, a digital-asset investment and infrastructure platform, and served as Chief Executive Officer of Onex Credit Partners, a $25 billion alternative credi

    10/8/25 7:59:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Financials

    Live finance-specific insights

    View All

    ETHZilla Reports Third Quarter 2025 Financial Results

    Company generates $4.1 million in revenue in first six weeks operating as ETHZilla; Accelerates RWA tokenization initiatives PALM BEACH, Fla., Nov. 14, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance (DeFi), today announced financial results for the third quarter ended September 30, 2025. Management Commentary "This quarter marked a transformative leap for ETHZilla, establishing us as a technology leader in DeFi and positioning us for real-world asset (RWA) toke

    11/14/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care